Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05985798 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This study is conducted to evaluate the efficacy and safety of sintilimab, bevacizumab plus TACE (Sin-Bev-TACE) compared with lenvatinib plus TACE (Len-TACE) for patients with advanced stage hepatocellular carcinoma (HCC).
Trial Details
NCT Number NCT05985798
Lead Sponsor Second Affiliated Hospital of Guangzhou Medical University
Collaborators: Affiliated Hospital of Guangdong Medical University, Zhongshan People's Hospital, Guangdong, China, Lecong Hospital, Shunde District, Foshan, First People's Hospital of Foshan, Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Conditions
(from sponsor)		 Hepatocellular Carcinoma Non-resectable
Enrollment 258 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov